Increased exercise tolerance after nitroglycerin oral spray: a new and effective therapeutic modality in angina pectoris

Circulation
A KimchiD T Mason

Abstract

The prophylactic antianginal efficacy of nitroglycerin (NTG) oral spray was assessed in 20 patients with angiographically documented coronary disease and stable angina pectoris. The evaluation was by a randomized crossover trial involving treadmill exercise testing. On study day 1, a control treadmill exercise test was performed, followed 30 minutes later by a second exercise test 2 minutes after administration of either placebo (group A, 10 patients) or NTG spray 0.8 mg (group B, 10 patients). One week later, on study day 2, the patients again underwent control treadmill exercise testing followed by a second exercise test after either NTG spray (group A) or placebo (group B). NTG spray delayed the onset of anginal pain during exercise by a mean of 100 +/- 64 seconds (p less than 0.001) in 13 patients and prevented pain entirely in seven. Placebo did not significantly delay the appearance of angina and prevented chest pain in only one patient. NTG spray increased treadmill exercise duration by 31% before the onset of angina (p less than 0.001); placebo did not significantly alter the duration of exercise. NTG spray abolished in six patients and delayed in 14 patients the onset of exercise-induced ST-segment depression of 1 mm (...Continue Reading

Citations

Apr 1, 1990·Cardiovascular Drugs and Therapy·R E GansserK F Bachmann
Feb 15, 1985·The American Journal of Cardiology·K K Teo, J H Horgan
Mar 25, 1988·The American Journal of Cardiology·K F Bachmann, R E Gansser
May 30, 1996·The American Journal of Cardiology·J A Parker
Dec 12, 2001·Pediatrics International : Official Journal of the Japan Pediatric Society·B UçarK Ozdamar
Nov 10, 1984·British Medical Journal·M HeberD A Chamberlain
Mar 26, 2014·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Udho Thadani
Jan 1, 1989·Intensive Care Medicine·J D EdwardsP Nightingale
Sep 21, 2013·Expert Opinion on Pharmacotherapy·Ashish K GuptaCarl J Pepine
Mar 1, 1986·Journal of Pharmaceutical Sciences·S W SandersH Jaeger
Feb 1, 1990·Mayo Clinic Proceedings·C Shub
Jan 1, 1986·The American Journal of Cardiology·J O ParkerB Farrell
Dec 14, 2002·The American Journal of Cardiology·Dean Towle Mason
Nov 27, 1992·The American Journal of Cardiology·E A Amsterdam
Dec 1, 1983·Journal of Pharmacokinetics and Biopharmaceutics·R Erb, W Stoltman
Nov 16, 1987·The American Journal of Cardiology·N Reichek
Jun 18, 2016·Cardiovascular Drugs and Therapy·Jason M Tarkin, Juan Carlos Kaski
Jun 25, 1987·The New England Journal of Medicine·J O Parker
Apr 1, 2017·Journal of Cardiovascular Pharmacology and Therapeutics·Santosh K PadalaPeter P Toth
Aug 12, 2008·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·James W Price, John R Price
Aug 6, 1992·The Journal of Pharmacy Technology : JPT : Official Publication of the Association of Pharmacy Technicians·D E Hilleman, U V Banakar
Jan 1, 1986·The Journal of International Medical Research·M Aärynen, K Soininen
Dec 31, 2020·BioMed Research International·Maryam JalaliSeyyed Mohammad Taghi Ayatollahi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.